Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Single Dose Brexpiprazole in Healthy Chinese Subjects
NCT03734354Phase 1Completed
- Sponsor
- Otsuka Holdings
- Start
- Apr 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of brexpiprazole orally disintegrating tablet in schizophrenia and major depressive disorder (MDD) (3 arms), sponsored by Otsuka Holdings. Primary endpoints: Peak Concentration up to 264 hours, Peak Time up to 264 hours and 4 more. Started Apr 2019; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
schizophreniamajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03734354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03734354.